A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy
Tsung‐I Hsu(National Health Research Institutes), Jan‐Jong Hung(Taipei Medical University), Wu‐Chou Su(National Cheng Kung University), Sin‐Jin Lin(National Cheng Kung University), Wen‐Chang Chang(National Cheng Kung University), Keduo Qian, Masuo Goto, Yi-Chang Wang(National Cheng Kung University), Yoshiki Kashiwada(Tokushima University), Qiang Wang(Sichuan University), Sang Yong Kim, Yu Zhao(Guangdong University of Technology), Chia-Yang Hung(National Cheng Kung University), Kuo‐Hsiung Lee(China Medical University), Ming-Derg Lai(National Cheng Kung University), Ying‐Jung Chen(National Cheng Kung University)
Cited by 33
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|The Lancet Oncology|2020|413
Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis
|Biomedicine & Pharmacotherapy|2022|282